Stockscreener 앱 받기
94.39
0.43%
0.40
전일 마감가:
$93.99
열려 있는:
$94.47
하루 거래량:
54.75M
Relative Volume:
9.28
시가총액:
$292.66B
수익:
$58.07B
순이익/손실:
$9.40B
주가수익비율:
31.35
EPS:
3.0113
순현금흐름:
$9.87B
1주 성능:
-0.27%
1개월 성능:
+3.33%
6개월 성능:
+34.69%
1년 성능:
+41.07%
1일 변동 폭
$93.51
$94.68
1주일 범위
$92.78
$96.43
52주 변동 폭
$61.24
$96.51
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
94.39 | 291.42B | 58.07B | 9.40B | 9.87B | 3.0113 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
Trend Review: Does AstraZeneca PLC Depositary Receipt have a sustainable dividendEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
AstraZeneca share price steadies after Thursday drop as traders eye Nasdaq-100 reshuffle - TechStock²
AstraZeneca’s Cell Therapy Manufacturing Facility, Maryland, USA - Pharmaceutical Technology
AstraZeneca (AZN) Weighs FDA Fast-Track Risks Amid Legal Concerns - GuruFocus
AstraZeneca (AZN) Acquires Modella AI to Boost Cancer Research - GuruFocus
AstraZeneca Acquires Modella AI to Accelerate Cancer Therapy Development - Intellectia AI
JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN) - MarketBeat
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
What Makes AstraZeneca (AZN) a Strong Growing Company? - Insider Monkey
AstraZeneca Spotlights 2025 Growth, 2026 Launch Wave and $80B 2030 Goal at JPM Conference - Yahoo Finance
The Newest Stock in the Nasdaq-100 Soared 549,000% Since Its IPO, and It's Still a Buy Right Now, According to Wall Street (Hint: Not Strictly a Tech Company) - The Motley Fool
Rep. Julia Letlow Buys AstraZeneca PLC (NASDAQ:AZN) Shares - MarketBeat
AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition - Pharmaceutical Technology
Manning & Napier Advisors LLC Sells 390,342 Shares of AstraZeneca PLC $AZN - MarketBeat
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale - marketscreener.com
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's Why - MarketBeat
Market Overview: Whats AstraZeneca PLC Depositary Receipts historical returnMarket Performance Recap & Intraday High Probability Alerts - baoquankhu1.vn
AstraZeneca: acquires Modella AI to strengthen its oncology research - marketscreener.com
AstraZeneca stock rating reiterated at Buy by Guggenheim ahead of Q4 results - Investing.com UK
AstraZeneca CFO on M&A Strategy and Obesity Market - marketscreener.com
AstraZeneca to acquire Modella AI to speed oncology drug research - Reuters
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe - GuruFocus
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI - GuruFocus
AstraZeneca acquires AI firm to boost research - breakingthenews.net
Risks Report: What technical charts say about AstraZeneca PLC Depositary Receipt stockJuly 2025 Fed Impact & Weekly Return Optimization Plans - Bộ Nội Vụ
Modella AI announces acquisition by AstraZeneca - marketscreener.com
AstraZeneca (AZN) Joins in Groundbreaking Genetic Research Initiative - GuruFocus
AstraZeneca (AZN) Progresses with Phase 3 TROPION-Lung17 Trial - GuruFocus
Walmart to join Nasdaq 100 on Jan. 20 as AstraZeneca exits - MSN
AstraZeneca (AZN) Set for Removal from Several Key Nasdaq Indexes - GuruFocus
SG Americas Securities LLC Grows Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to be replaced by Walmart in the Nasdaq-100 index — Check dates - The Financial Express
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $215.25 - 富途牛牛
Oliver Luxxe Assets LLC Buys 13,350 Shares of AstraZeneca PLC $AZN - MarketBeat
The Truth About AstraZeneca plc: Wall Street Sleeper Stock Or Overhyped Dinosaur? - AD HOC NEWS
The Truth About AstraZeneca plc: Is This Pharma Giant Still Worth Your Money? - AD HOC NEWS
Berenberg Bank Remains Bullish on AstraZeneca PLC (AZN) – Here’s Why - Insider Monkey
AstraZeneca stock set for Nasdaq-100 exit on Jan. 20 as Walmart takes its slot — what AZN investors watch next - TechStock²
Walmart to join Nasdaq 100 from January 20 as AstraZeneca exits the index - MSN
The Truth About AstraZeneca plc: Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Walmart to Join Nasdaq 100 Index on January 20 as AstraZeneca Exits - scanx.trade
AstraZeneca: Oncology Dominance Justifies New All-Time Highs (NASDAQ:AZN) - Seeking Alpha
Walmart Set to Enter Nasdaq 100 on January 20, Replacing AstraZeneca - Bitget
HB Wealth Management LLC Has $3.65 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
AstraZeneca - Britannica
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca - MSN
Walmart joins Nasdaq 100, $19 billion investment surge coming - Cryptopolitan
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):